Radiation Therapy
Also known as: Brachytherapy, Radiotherapy, Dandruff, Seborrhea, Seborrheic
Methodology & AI Transparency ⓘ
Radiation Therapy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is radiation therapy? Radiation therapy is a cancer treatment.
- 2 Real-world patient consensus: Synonyms for Radiation Therapy (L58.9): Brachytherapy, Radiotherapy, Dandruff (Cancer & Oncology).
- 3 Typical cash cost range: Primary evaluation for Radiation Therapy incorporates immunohistochemistry [Radiation Therapy L58.9] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Radiation Therapy monitoring tracks Pathology / Molecular in Radiation Therapy (L58.9: Genomic Staging) toward Guideline-concordant surveillance (L58.9).
Ask our AI Specialists anything about Radiation Therapy
What Is Radiation Therapy?
What is radiation therapy? Radiation therapy is a cancer treatment. It uses high doses of radiation to kill cancer cells and stop them from spreading. It may also be used for easing cancer symptoms. Radiation therapy may damage healthy cells. They can usually repair themselves more easily than cancer cells. You may need days or weeks of treatment before the radiation starts killing cancer cells. But cancer cells should keep dying for weeks or months after your treatment ends. When is radiation therapy used for cancer treatment? Radiation therapy treats many types of cancer. It may be used at different times or for different reasons during your treatment.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Radiation Therapy (L58.9) center on angiogenesis [Radiation Therapy L58.9]. Cross-referenced with NIH MeSH (Radiotherapy), targeted cancer & oncology interventions aim to normalize Pathology / Molecular in Radiation Therapy (L58.9: Genomic Staging).
Common Symptoms & Clinical Signs
- • The type of cancer
- • The size of the cancer
- • Presentation of Radiation Therapy (L58.9): abnormality detected early in Radiation Therapy (L58.9: on age-appropriate screening)
- • Secondary Radiation Therapy clinical sign: persistent painless lump, in Radiation Therapy (L58.9: non-healing ulcer/mole change,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Radiation Therapy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L58.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Radiation Therapy (L58.9: Genomic Staging) | Guideline-concordant surveillance (L58.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Radiation Therapy (L58.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (L58.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Radiation Therapy (L58.9: Organ Function Panel) | Preserved renal/hepatic clearance (L58.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Radiation Therapy
Treatment selection for Radiation Therapy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Radiation Therapy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Health-related quality of life scores of metastatic pancreatic cancer patients: What a 466-Participant Study Found This is the first study to systematically derive EORTC QLQ-C30 reference values for mPC. BMC cancer • 2022-05-20 • Phase III Randomized Trial | N = 466 | 93/100 | PMID 35596182 ↗ |
| New Insights on Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A: What a 447-Participant Study Found We did not find sufficient evidence to suggest any detrimental effect of pelvic XRT on the treatment effect from denosumab on percent BMD change, with only an approximately 5% incidence of clinical fractures. International journal of radiation oncology, biology, physics • 2024-05-01 • Phase III Randomized Trial | N = 447 | 93/100 | PMID 37924987 ↗ |
| New Insights on Skin-applied Betamethasone Valerate As a Prophylactic Agent to Prevent Acute: What a 2,018,150-Participant Study Found Although prophylactic use of betamethasone significantly reduced the composite outcome of the proportion of patients developing grade 2 and grade 3 radiation dermatitis, it did not reduce the proportion of patients developing... International journal of radiation oncology, biology, physics • 2021-01-01 • Phase III Randomized Trial | N = 2,018,150 | 90/100 | PMID 32853709 ↗ |
| New Insights on Early toxicity of moderately hypofractionated radiation therapy in breast cancer: What a 1,265-Participant Study Found Early AEs were mild and do not raise safety concerns for 3-week-RT in women receiving nodal RT. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2025-06-15 • Phase III Randomized Trial | N = 1,265 | 90/100 | PMID 40097073 ↗ |
| New Insights on Breast-Conserving Surgery with or without Irradiation in Early Breast: What a 1,326-Participant Study Found Omission of radiotherapy was associated with an increased incidence of local recurrence but had no detrimental effect on distant recurrence as the first event or overall survival among women 65 years of age or older with... The New England journal of medicine • 2023-02-16 • Phase III Randomized Trial | N = 1,326 | 90/100 | PMID 36791159 ↗ |
Radiation Therapy Patient Community & “People Like Me” Threads
Filter Radiation Therapy community threads and patient logs by age, biological sex, dosage, and treatment duration.